Despite substantial treatment advances, cardiovascular diseases (CVDs) remain the leading cause of death in the world. Recent research has revealed that nearly seven in ten cases of CVD can be explained by modifiable risk factors: such as high blood pressure, abdominal obesity, low education, smoking, dyslipidaemia, poor diet, strength and physical activity, diabetes, depression, and air pollution. Diagnosis and management of these risk factors are essential to preventing premature deaths due to CVD. However, there remains a significant risk of cardiovascular events despite optimal risk factor management. Other less understood, potentially modifiable risk factors include inflammatory, pro-thrombotic and metabolic pathways, and warrant further study.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Experts discuss optimization of multidisciplinary care of alpha-mannosidosis along the patient’s lifespan.
Watch a leading expert discuss the need for personalised obesity treatment including current evidence for cardiovascular outcomes.
touchENDOCRINOLOGY was delighted to speak with Editorial Board member Dr Deep Dutta, a senior endocrinologist at the CEDAR Superspecialty Clinics, New Delhi, India. Throughout this interview, he summarizes the key messages from his late-breaking abstract session ‘Ailing Heart, Broken Vessels’, presented at the 60th European Association for the Study of Diabetes (EASD) annual meeting in Madrid, Spain.
Hypertension affects up to 40% of the adult population worldwide,1 and according to the World Health Organization’s 2021 estimates, globally 1.28 billion adults between 18 and 79 years are affected.2 Of these, 85% have essential hypertension3 and the remainder have secondary hypertension, which is potentially ...
In the early 1970s, the discovery of statin by Dr Akira Endo changed the fate of cardiovascular disease prevention and the treatment of atherosclerosis. It was during this period that the rate-limiting step in cholesterol biosynthesis was revealed, and the ...
Chylomicronaemia refers to the pathological presence of large, circulating, intestinally derived chylomicrons.1 Clinical features of chylomicronaemia syndrome include lipaemic plasma, lipaemia retinalis, eruptive xanthomas, hepatosplenomegaly, neurological symptoms such as mental fog and mood changes and, most importantly, increased risk of ...
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
Watch specialists within an MDT plus a patient discuss incretin-based dual agonists and educational strategies for patients with T2D and obesity
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycaemia resulting from insulin resistance, inefficient insulin secretion and disproportionate glucagon secretion.1Â It has been reported to be an expanding global health issue of the 21st century, and one of ...
Watch leading specialists within an MDT plus a patient with T2D discuss the use of antihyperglycemic therapies to control both T2D and obesity
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.